ClinicalTrials.gg
Not yet recruitingNCT07468838UroDNAUpdated Mar 16, 2026

Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer

An observational study in Prostate Cancer and Bladder Cancer, sponsored by Institut Cancerologie de l'Ouest. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Institut Cancerologie de l'Ouest · Observational

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Prostatic Neoplasms by Institut Cancerologie de l'Ouest — 2 open to participants now, 5 under way, none of them phase 3. Prostatic Neoplasms · Institut Cancerologie de l'Ouest.

Started
2026
with 1 other
Observational
2 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Prostatic Neoplasms by Institut Cancerologie de l'Ouest, this one is one of 2 that started in 2026, is one of 2 observational ones, and was the 11th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 11 studies in Prostatic Neoplasms by Institut Cancerologie de l'Ouest are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Prostatic Neoplasms by Institut Cancerologie de l'Ouest, or all of them as a file.
02

Study summary

The UroDNA study is a feasibility study (RIPH category 3) aimed at evaluating the analysis of circulating tumour DNA in urine (urinary cfDNA) as a non-invasive monitoring tool in patients with prostate or bladder cancer. Urine samples will be collected at different times during the course of treatment to define the optimal conditions for cfDNA collection, extraction and analysis, and to explore the detection of tumour mutation profiles. This study does not involve any experimental treatment. Its objective is to validate the technical and clinical feasibility of a molecular monitoring urine test, which could offer a simple and non-invasive alternative to improve the management of urological cancers.

Read the detailed description

Patients will be included as they are admitted to the facility. If they agree to participate, two urine samples will be collected at the start of treatment and at the end of the treatment sequence.

03

Conditions studied

  • Prostate Cancer
  • Bladder Cancer

Keywords

  • urinary cfDNA
  • prostate cancer
  • bladder cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with prostate or bladder cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1) Five patients for each of the following cancers :

  • Patients with high-risk localised prostate cancer eligible for high-dose radiotherapy, or
  • Patients with mHSPC eligible for docetaxel chemotherapy, or
  • Patients with mCRPC in treatment eligible for luPSMA treatment, or
  • Patients with localised bladder cancer eligible for chemotherapy or,
  • Patients with bladder cancer eligible for enfortumab vedotin (EV) plus pembrolizumab (EV-Pembro)

Exclusion criteria

Exclusion Criteria:

  1. History of cancer in the 5 years prior to entering the trial other than basal cell skin cancer or cervical carcinoma in situ,
  2. Women who are pregnant, likely to become pregnant or breastfeeding,
  3. Persons deprived of their liberty, under judicial protection, under guardianship or placed under the authority of a guardian, Inability to undergo medical follow-up for the trial for geographical, social or psychological reasons.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • prostate cancer eligible for high-dose-rate radiotherapy

    Patients with high-risk localised prostate cancer who are eligible for high-dose-rate radiotherapy

  • prostate cancer eligible for docetaxel chemotherapy

    Patients with mHSPC eligible for docetaxel chemotherapy

  • prostate cancer eligible for treatment with luPSMA

    Patients with mCRPC in second-line treatment eligible for treatment with luPSMA

  • Bladder cancer eligible for neoadjuvant chemotherapy

    Patients with localised bladder cancer eligible for neoadjuvant chemotherapy

  • metastatic bladder cancer eligible for enfortumab vedotin (EV) plus pembrolizumab (EV-Pembro)

    Patients with metastatic bladder cancer eligible for enfortumab vedotin (EV) plus pembrolizumab (EV-Pembro)

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., Enfortumab vedotinStudies of Enfortumab vedotinEnfortumab vedotin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. concentration of cfDNA obtained in urine

    concentration of cfDNA obtained in urine

    Time frame: 6 months

Secondary outcomes

  1. Distribution of circulating tumour DNA sizes in urine (urinary cfDNA)

    Distribution of circulating tumour DNA sizes in urine (urinary cfDNA)

    Time frame: 6 months

  2. mutational load variation

    mutational load variation

    Time frame: 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Obtaining preliminary data and evaluation of feasibility

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Dec 2027, 19 months later.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 19 months is below that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 13, 2026
StartEst.
May 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07468838
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
May 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 16, 2026

Study contacts

Laetitia HIMPE
Contact
promotionrc@ico.unicancer.fr
+33 240679747
Manon MD DE VRIES BRILLAND
principal investigator · ICO Angers

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion